CD28 and neoplasm: This effect could actually be increased by trispecific antibodies [24,49] and manifests that CD28 on MM cells and TC co-stimulation can play an important role in overcoming drug resistance in RRMM, e.g., after daratumumab treatment, by improving tumor recognition and long-term TC activation [50,51].